KRAS Cancer Connect - KRAS Kickers

09/27/2026

Congratulations the pocket you found, is making KRAS druggable!! Thank YOU Stephenson for recognizing this rockstar breakthrough that has created a new class of drug treatments!! Terri Conneran

Kevan Shokat, PhD, gave lung cancer survivor and KRAS Kickers found...

09/19/2026

https://www.kraskickers.org/post/kras-kickers-on-ai-trust-and-trial-search-at-wclc-2026

KRAS care partner and advocate Chris Conneran joined an international discussion on how artificial intelligence is shaping cancer care, with a focus on patient trust and transparency.

09/11/2026

JUST ANNOUNCED! KRAS Kickers Webinar with Dr. Salman Punekar — Monday, September 14, 1:00–2:30 PM EDT. Join a live conversation on the latest KRAS cancer research and what it means for people living with cancer today, featuring an expert oncologist and a cancer patient. Register now: https://wix.to/Lx8yzrN

09/04/2026

This research is particularly relevant to people with RAS mutations for which there is currently no FDA approved mutation specific targeted therapy in lung cancer.

https://www.kraskickers.org/post/lung-cancer-daraxonrasib-nejm-sep2026?fbclid=IwY2xjawUIBsRwZG9mBWV4dG4DYWVtAjExAHNydGMGYXBwX2lkEDIyMjAzOTE3ODgyMDA4OTIAAR6K30ngA38wm_GH6NJebtd3xsx_93VSgCh5CNKv4HGzBeV-Mc6cj11kHM6jOw_aem_ucUF3oYEM7ufbGbcJ4L_vw

By Terri Conneran, Founder, KRAS KickersReviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone HealthFor this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because d...

09/03/2026

Join us at the FLASCO Breaking Barriers Summit 2026 in Coral Gables — September 18–19. Brian Owen, KRAS Kicker, will share his late wife Betty’s story to raise awareness and multiply hope for those affected by pancreatic cancer. Be part of this powerful evening of stories, learning, and community. Learn more and RSVP: https://wix.to/p1Kg9bg

09/01/2026

Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment strategy, clinical trials, and next-generation drugs.

08/29/2026

Register: https://kraskickers.zoom.us/webinar/register/WN_CrkctKKPSwGuzV7ED42FEA #/registration

08/26/2026

just FDA approved for cancer second line therapy! Kick pdac KRAS!

02/23/2026

There’s nothing quite like this moment! 💙

Patients. Care partners. Researchers. Advocates.
All in one room at University of California, San Francisco — united by one shared goal: to kick cancer’s KRAS! 💙

This is why we exist.

To bring the science closer to the people it impacts.
To turn research into real conversations.
To replace isolation with community.
To transform hope into action.

When patients and researchers stand shoulder to shoulder, progress feels different. It feels personal. It feels urgent. It feels possible.

Hope shared is hope multiplied.

Together, we can kick cancer’s KRAS!! 💙💜🤍

(Huge shoutout and thank you to and the Shokat Lab for hosting us and sharing how far the RAS research has come and where it’s going! 🙌)

02/19/2026

San Francisco, we’re ready. 💙

The KRAS Kickers team is on the ground and counting down the hours until tomorrow’s KRAS Cancer Connect — bringing patients, care partners, researchers, and advocates together in one powerful space.

We can’t wait to connect, learn, and remind every single person in the room that they are not alone.

Together, we can kick cancer’s KRAS!!